Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyMedical Mutual - Ohio Kisqali Prior Auth Policy Up…
    Ask Trek AI about this page
    CurrentMedical Mutual - OhioPolicy N/A

    Kisqali (ribociclib) and Kisqali Femara Co-Pack coverage

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, clinical coverage criteria, and approval durations for Kisqali (ribociclib) alone or as a co-pack with letrozole for treating HR+, HER2- advanced or high-risk early breast cancer in adults; applies to Medical Mutual - Ohio pharmacy benefit reviews.

    Policy Summary
    PayerMedical Mutual - Ohio
    PolicyKisqali (ribociclib) and Kisqali Femara Co-Pack coverage
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewFeb 19, 2026
    Next Review DateFeb 19, 2026
    Key ActionObtain prior authorization and ensure initial prescribing is by or in consultation with a hematologist or oncologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial approval duration
    1 year

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Extended approval duration
    HR+, HER2-Target tumor biomarker profile
    Oncology requiredSpecialist prescriber
    Men & pre/postmenopausal womenCovered populations

    Coverage and Medical Necessity Criteria

    Medical necessity criteria

    Coverage is recommended when ALL of the following criteria are met for the specified populations:

    Core eligibility: Patient has recurrent, advanced, or metastatic disease, or early disease (stage II or III) at high risk of recurrence; AND patient has hormone receptor–positive (ER+ and/or PR+) disease; AND patient has HER2‑negative breast cancer

    High risk of recurrence includes any lymph node involvement; tumor size > 5 cm; or tumor size 2–5 cm with either grade 2 (and high genomic risk or Ki‑67 ≥ 20%) or grade 3 disease.

    Women: population- and therapy-specific options: For women, ONE of: (i) postmenopausal and Kisqali used as first-line endocrine therapy in combination with anastrozole, exemestane, letrozole, OR fulvestrant; OR (ii) postmenopausal and Kisqali Femara Co‑Pack used as first-line endocrine therapy; OR (iii) postmenopausal and Kisqali used as second‑line or subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously; OR (iv) premenopausal or perimenopausal with ovarian suppression/ablation (GnRH agonist, bilateral oophorectomy, or ovarian irradiation) AND one of the options: first‑line with an AI or fulvestrant, Kisqali Femara Co‑Pack first‑line, or second‑line with fulvestrant if no prior CDK4/6 inhibitor

    Premenopausal/perimenopausal patients must receive ovarian suppression/ablation (examples: leuprolide, triptorelin, goserelin).

    Men: population- and therapy-specific options: For men, ONE of: (i) Kisqali used as first‑line endocrine therapy in combination with anastrozole, exemestane, letrozole, OR fulvestrant; OR (ii) Kisqali Femara Co‑Pack used as first‑line endocrine therapy; OR (iii) Kisqali used as second‑line or subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously

    Men receiving an aromatase inhibitor must receive concomitant GnRH agonist for testicular suppression (examples: leuprolide, triptorelin, goserelin).

    Other guideline-supported indications: Any other indication cited in the NCCN guidelines as category 1, 2A, or 2B may be approved

    Prescriber must provide specific diagnosis documentation.

    Continuation of therapy: Approve continuation if prescriber provides evidence of beneficial response warranting continuation of therapy

    Initial approval duration: 6 months; extended approval duration: 1 year.

    Uses not listed in this policy will be reviewed on a case-by-case basis and require submission of supporting evidence for efficacy and medical necessity. Such requests may be considered investigational or not recommended for approval unless the reviewer determines there is sufficient clinical evidence and documented need to support coverage.

    Therapy may be denied if the drug or service is determined to be investigational/experimental or not medically necessary following review. The Company may also deny reimbursement if the treatment is not within the member’s scope of benefits or if inappropriate or excessive billing or practice patterns are identified. The Company reserves the right to modify, revise, change, apply, and interpret this policy at its sole discretion.

    RegimenIndication / line of therapyCoverage status
    Ribociclib in combination with anastrozole
    HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression)
    Ribociclib in combination with exemestane
    HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression)
    Ribociclib in combination with letrozole
    HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression)
    Ribociclib in combination with fulvestrant
    HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy or second‑line/subsequent therapy with fulvestrant only if no prior CDK4/6 inhibitor exposure (postmenopausal or premenopausal with ovarian suppression)
    Kisqali Femara Co‑Pack (ribociclib + letrozole)
    HR+, HER2‑ negative advanced or metastatic breast cancer; first‑line endocrine therapy (postmenopausal or premenopausal with ovarian suppression)

    Prior Authorization Codes and Biomarker Thresholds

    Prior authorization affected codesmixed
    affected codesplaceholder for pharmacy benefit codes referenced by payer
    Ki-67 — numeric biomarker threshold
    Ki-67 threshold>= 20%
    Use in defining high genomic riskKi-67 ≥ 20% qualifies tumor 2-5 cm with grade 2 as high genomic risk
    Context of applicationApplied when determining high risk of recurrence for early-stage (stage II/III) disease

    Prior Authorization, Prescriber Requirements, and Documentation

    Prior Authorization

    Prior Authorization Recommended

    Prior authorization is recommended for pharmacy benefit coverage of Kisqali/Kisqali Femara Co-Pack. Initial prescribing must be by or in consultation with a physician who specializes in the condition being treated; specifically, the drug must be prescribed by or in consultation with a hematologist or oncologist for initial therapy. All approvals for initial therapy are provided for the initial approval duration noted in the policy.

    • Prior authorization recommended for pharmacy benefit
    • Initial prescriber: hematologist or oncologist (or in consultation with one)
    • Initial approvals provided for the initial approval duration specified in the policy
    Step Therapy

    Line of Therapy Constraints

    Line of therapy constraints apply based on prior exposure to CDK4/6 inhibitors and menopausal status. For postmenopausal patients, Kisqali may be used as first-line endocrine therapy in combination with anastrozole, exemestane, letrozole, or fulvestrant, or as first-line when using the Kisqali Femara Co-Pack. Kisqali may be used as second-line or subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously. For premenopausal or perimenopausal patients receiving ovarian suppression/ablation, the same first-line and restricted second-line rules apply. Equivalent line-of-therapy rules apply for men meeting criteria, with concomitant GnRH agonist when combined with an aromatase inhibitor.

    Definitions and Risk Stratification

    High risk of recurrence — definition
    Any lymph node involvementPresence of any lymph node metastasis qualifies as high risk of recurrence
    Tumor size > 5 cmPrimary tumor size greater than 5 cm qualifies as high risk
    Tumor size 2–5 cm with grade criteriaTumor 2–5 cm with either grade 2 (and high genomic risk or Ki-67 ≥ 20%) or grade 3 disease qualifies as high risk

    Line of Therapy Criteria

    Line of therapy — first-line | second-line

    Line of therapy options: First‑line endocrine therapy in combination with an aromatase inhibitor (anastrozole, exemestane, letrozole) or fulvestrant; OR second‑line/subsequent endocrine therapy in combination with fulvestrant only if a CDK4/6 inhibitor has not been used previously

    Different rules apply by patient group: premenopausal/perimenopausal patients require ovarian suppression/ablation; men require concomitant GnRH agonist when receiving an aromatase inhibitor.

    Hormone Receptor and HER2 Status; Proliferation Index

    HR (ER/PR) and HER2 — biomarker requirements
    Hormone receptor status requiredHR+ defined as estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)
    HER2 status requiredHER2-negative disease required
    Combined biomarker requirementPatient must have HR+ (ER+ and/or PR+) AND HER2-negative breast cancer
    Ki-67 — proliferation index threshold
    Proliferation index threshold>= 20% Ki-67 defines high proliferation (used to identify high genomic risk)
    Role in early diseaseKi-67 ≥ 20% applied to tumors 2–5 cm with grade 2 to qualify as high risk of recurrence

    Clinical Background

    Ribociclib is a cyclin-dependent kinase (CDK4/6) inhibitor that prevents phosphorylation of the retinoblastoma protein (Rb), producing G1 cell-cycle arrest and decreased cellular proliferation in estrogen receptor–positive (ER+) breast cancer. It is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for appropriate patients and is available as single-agent tablets or co‑packaged with letrozole.

    Policy Revision History

    2026-02-19policy_review_and_revisionLatest

    Annual review completed; policy last revised and reviewed on 02/19/2026.

    initial_approval_settings

    Initial and extended approval durations defined (initial 6 months; extended 1 year).

    Policy Summary
    PayerMedical Mutual - Ohio
    PolicyKisqali (ribociclib) and Kisqali Femara Co-Pack coverage
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewFeb 19, 2026
    Next Review DateFeb 19, 2026
    Key ActionObtain prior authorization and ensure initial prescribing is by or in consultation with a hematologist or oncologist.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaPrior Authorization Codes and Biomarker ThresholdsPrior Authorization, Prescriber Requirements, and DocumentationDefinitions and Risk StratificationLine of Therapy CriteriaHormone Receptor and HER2 Status; Proliferation IndexClinical BackgroundPolicy Revision History
    • First-line use: Kisqali + aromatase inhibitor or fulvestrant, or Kisqali Femara Co-Pack as first-line
    • Second-line/subsequent use with fulvestrant only if no prior CDK4/6 inhibitor exposure
    • Premenopausal/perimenopausal patients must have ovarian suppression/ablation when applicable
    • Men: follow similar first-/second-line rules; use GnRH agonist when combined with an aromatase inhibitor
    Documentation Required

    Supporting Documentation and Denial Triggers

    The Company may request additional documentation to support medical necessity. Documentation may include patient medical records, diagnostic test results, and provider credentials. Failure to provide requested documentation may result in denial of coverage. The Company may also deny reimbursement if the drug or service is deemed not medically necessary, investigational/experimental, outside the member's benefit scope, or if there is a pattern of inappropriate or excessive billing.

    • Company may request patient records, test results, and provider credentials
    • Additional documentation must be made available upon request to support medical necessity
    • Denial triggers include: not medically necessary, investigational/experimental, outside scope of benefits, or inappropriate/excessive billing patterns
    Referenced in both sexes criteriaKi-67 threshold appears in criteria for women and men when assessing high risk of recurrence